

Adrian Towse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11983373/publications.pdf>

Version: 2024-02-01

94
papers

3,119
citations

159525

30
h-index

168321

53
g-index

99
all docs

99
docs citations

99
times ranked

3056
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Performance-Based Risk-Sharing Arrangementsâ€™ Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force. Value in Health, 2013, 16, 703-719. | 0.1 | 237 |
| 2 | Differential pricing for pharmaceuticals: reconciling access, R&D and patents. International Journal of Health Care Finance and Economics, 2003, 3, 183-205. | 1.2 | 194 |
| 3 | Prospective Observational Studies to Assess Comparative Effectiveness: The ISPOR Good Research Practices Task Force Report. Value in Health, 2012, 15, 217-230. | 0.1 | 151 |
| 4 | Challenges in the Development and Reimbursement of Personalized Medicineâ€™ Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. Value in Health, 2012, 15, 1162-1171. | 0.1 | 119 |
| 5 | A Health Economics Approach to US Value Assessment Frameworksâ€™ Summary and Recommendations of the ISPOR Special Task Force Report [7]. Value in Health, 2018, 21, 161-165. | 0.1 | 113 |
| 6 | Canâ€™t Get No Satisfaction? Will Pay for Performance Help?. Pharmacoeconomics, 2010, 28, 93-102. | 1.7 | 102 |
| 7 | Learning from Thailand's health reforms. BMJ: British Medical Journal, 2004, 328, 103-105. | 2.4 | 88 |
| 8 | Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. European Journal of Health Economics, 2019, 20, 427-438. | 1.4 | 85 |
| 9 | Operationalizing Value-Based Pricing of Medicines. Pharmacoeconomics, 2013, 31, 1-10. | 1.7 | 84 |
| 10 | Gene therapy: evidence, value and affordability in the US health care system. Journal of Comparative Effectiveness Research, 2018, 7, 15-28. | 0.6 | 84 |
| 11 | The Economics of Gene Therapy and of Pharmacogenetics. Value in Health, 2002, 5, 5-13. | 0.1 | 79 |
| 12 | Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis. Value in Health, 2017, 20, 213-216. | 0.1 | 79 |
| 13 | Should NICE's threshold range for cost per QALY be raised? Yes. BMJ: British Medical Journal, 2009, 338, b181-b181. | 2.4 | 78 |
| 14 | Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context. Health Economics (United Kingdom), 2015, 24, 294-301. | 0.8 | 76 |
| 15 | Assessing A Structured, Quantitative Health Outcomes Approach To Drug Risk-Benefit Analysis. Health Affairs, 2007, 26, 684-695. | 2.5 | 75 |
| 16 | Using QALYs in Cancer. Pharmacoeconomics, 2011, 29, 673-685. | 1.7 | 74 |
| 17 | Biosimilars: How Can Payers Get Long-Term Savings?. Pharmacoeconomics, 2016, 34, 609-616. | 1.7 | 67 |
| 18 | Orphan drugs policies: a suitable case for treatment. European Journal of Health Economics, 2014, 15, 335-340. | 1.4 | 64 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation. <i>Health Policy</i> , 2017, 121, 1025-1030. | 1.4 | 63 |
| 20 | Approaches to Aggregation and Decision Making – A Health Economics Approach: An ISPOR Special Task Force Report [5]. <i>Value in Health</i> , 2018, 21, 146-154. | 0.1 | 59 |
| 21 | Real-world evidence for coverage decisions: opportunities and challenges. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 1133-1143. | 0.6 | 59 |
| 22 | Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 360-366. | 1.1 | 48 |
| 23 | Objectives, Budgets, Thresholds, and Opportunity Costs – A Health Economics Approach: An ISPOR Special Task Force Report [4]. <i>Value in Health</i> , 2018, 21, 140-145. | 0.1 | 48 |
| 24 | Establishing a reasonable price for an orphan drug. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 31. | 0.6 | 47 |
| 25 | Economic Incentives for Evidence Generation: Promoting an Efficient Path to Personalized Medicine. <i>Value in Health</i> , 2013, 16, S39-S43. | 0.1 | 46 |
| 26 | The Drug Budget Silo Mentality in Europe: An Overview. <i>Value in Health</i> , 2003, 6, S1-S9. | 0.1 | 43 |
| 27 | Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics. <i>Journal of Personalized Medicine</i> , 2017, 7, 10. | 1.1 | 43 |
| 28 | Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?. <i>European Journal of Health Economics</i> , 2012, 13, 1-5. | 1.4 | 42 |
| 29 | Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. <i>American Journal of Managed Care</i> , 2015, 21, 632-40. | 0.8 | 41 |
| 30 | National Institute for Clinical Excellence (NICE): Is Economic Appraisal Working?. <i>Pharmacoeconomics</i> , 2002, 20, 95-105. | 1.7 | 34 |
| 31 | Indication-specific pricing of pharmaceuticals in the US healthcare system. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 397-404. | 0.6 | 33 |
| 32 | Can and should value-based pricing be applied to molecular diagnostics?. <i>Personalized Medicine</i> , 2013, 10, 61-72. | 0.8 | 30 |
| 33 | European Union Pharmaceutical Markets: A Case for Differential Pricing?. <i>International Journal of the Economics of Business</i> , 2015, 22, 263-275. | 1.0 | 29 |
| 34 | Medical negligence and the NHS: an economic analysis. <i>Health Economics (United Kingdom)</i> , 1999, 8, 93-101. | 0.8 | 25 |
| 35 | Setting Cost-Effectiveness Thresholds As A Means To Achieve Appropriate Drug Prices In Rich And Poor Countries. <i>Health Affairs</i> , 2011, 30, 1529-1538. | 2.5 | 25 |
| 36 | Mapping Priority Setting in Health in 17 Countries Across Asia, Latin America, and sub-Saharan Africa. <i>Health Systems and Reform</i> , 2016, 2, 71-83. | 0.6 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Paying for Cures: Perspectives on Solutions to the "Affordability Issue". Value in Health, 2018, 21, 276-279. | 0.1 | 25 |
| 38 | If it ain't broke, don't price fix it: the OFT and the PPRS. Health Economics (United Kingdom), 2007, 16, 653-665. | 0.8 | 24 |
| 39 | Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment?. Value in Health, 2019, 22, 677-683. | 0.1 | 23 |
| 40 | Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned. Journal of Personalized Medicine, 2013, 3, 288-305. | 1.1 | 22 |
| 41 | APPROACHES TO IDENTIFYING, MEASURING, AND AGGREGATING ELEMENTS OF VALUE. International Journal of Technology Assessment in Health Care, 2013, 29, 360-364. | 0.2 | 21 |
| 42 | The Efficient Use Of Pharmaceuticals: Does Europe Have Any Lessons For A Medicare Drug Benefit?. Health Affairs, 2003, 22, 42-45. | 2.5 | 20 |
| 43 | Affordability of New Technologies: The Next Frontier. Value in Health, 2018, 21, 249-251. | 0.1 | 19 |
| 44 | The Genomic Revolution: Is the Real Risk Under-Investment Rather than Bankrupt Health Care Systems?. Journal of Health Services Research and Policy, 2000, 5, 253-255. | 0.8 | 17 |
| 45 | PAYER PERSPECTIVES ON FUTURE ACCEPTABILITY OF COMPARATIVE EFFECTIVENESS AND RELATIVE EFFECTIVENESS RESEARCH. International Journal of Technology Assessment in Health Care, 2015, 31, 90-98. | 0.2 | 16 |
| 46 | A Strategy to Support Efficient Development and Use of Innovations in Personalized Medicine and Precision Medicine. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1082-1087. | 0.5 | 15 |
| 47 | A REVIEW OF HEALTH TECHNOLOGY APPRAISALS: CASE STUDIES IN ONCOLOGY. International Journal of Technology Assessment in Health Care, 2013, 29, 101-109. | 0.2 | 14 |
| 48 | Is rate of return pricing a useful approach when value-based pricing is not appropriate?. European Journal of Health Economics, 2019, 20, 945-948. | 1.4 | 14 |
| 49 | Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies. Bulletin of the World Health Organization, 2005, 83, 301-7. | 1.5 | 14 |
| 50 | Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy. Applied Health Economics and Health Policy, 2022, 20, 651-667. | 1.0 | 14 |
| 51 | New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options. SSRN Electronic Journal, 0, , . | 0.4 | 13 |
| 52 | Incentives for R&D for New Antimicrobial Drugs. International Journal of the Economics of Business, 2011, 18, 331-350. | 1.0 | 13 |
| 53 | International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework. Journal of Clinical Oncology, 2016, 34, 2936-2937. | 0.8 | 12 |
| 54 | Value assessment in precision cancer medicine. Journal of Cancer Policy, 2017, 11, 48-53. | 0.6 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | A framework to guide the optimal development and use of real-world evidence for drug coverage and formulary decisions. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 1145-1152. | 0.6 | 12 |
| 56 | Considering Severity in Health Technology Assessment: Can We Do Better?. <i>Value in Health</i> , 2022, 25, 1399-1403. | 0.1 | 12 |
| 57 | The UK Pharmaceutical Market. <i>Pharmacoeconomics</i> , 1996, 10, 14-25. | 1.7 | 11 |
| 58 | Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi-stakeholder, international workshop. <i>BMC Health Services Research</i> , 2021, 21, 412. | 0.9 | 11 |
| 59 | Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. <i>Value in Health</i> , 2021, 24, 1628-1633. | 0.1 | 11 |
| 60 | The Pros and Cons of a Single Euro-Price For Drugs. <i>Pharmacoeconomics</i> , 1998, 13, 271-276. | 1.7 | 10 |
| 61 | Net Clinical Benefit: The Art and Science of Jointly Estimating Benefits and Risks of Medical Treatment. <i>Value in Health</i> , 2010, 13, S30-S32. | 0.1 | 10 |
| 62 | Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment – Rationale and Empirical Support. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 400-406. | 0.5 | 10 |
| 63 | How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?. <i>Value in Health</i> , 2021, 24, 625-631. | 0.1 | 9 |
| 64 | Drugs and Vaccines for Developing Countries. , 2012, , . | | 8 |
| 65 | Futurescapes: evidence expectations in the USA for comparative effectiveness research for drugs in 2020. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 385-400. | 0.6 | 8 |
| 66 | The future of comparative effectiveness and relative efficacy of drugs: an international perspective. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 419-427. | 0.6 | 8 |
| 67 | Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting?. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 13. | 0.6 | 8 |
| 68 | Reforming the Cancer Drug Fund. <i>BMJ</i> , The, 2014, 349, g7276-g7276. | 3.0 | 7 |
| 69 | Not cost-effective at zero price: valuing and paying for combination therapies in cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 331-333. | 0.7 | 7 |
| 70 | UNDERSTANDING VARIATIONS IN RELATIVE EFFECTIVENESS: A HEALTH PRODUCTION APPROACH. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 363-370. | 0.2 | 6 |
| 71 | Should We Pay for Scientific Knowledge Spillovers? The Underappreciated Value of ‘Failed’ R&D Efforts. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, 1-17. | 0.2 | 6 |
| 72 | Futurescapes: expectations in Europe for relative effectiveness evidence for drugs in 2020. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 401-418. | 0.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Cornerstones of "fair" drug coverage: appropriate cost-sharing and utilization management policies for pharmaceuticals. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 537-547. | 0.6 | 5 |
| 74 | Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 5 |
| 75 | The Pricing and Reimbursement of Pharmaceuticals. <i>Pharmacoeconomics</i> , 1994, 6, 36-38. | 1.7 | 4 |
| 76 | Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 268-277. | 0.9 | 4 |
| 77 | IS THE LINK BETWEEN HEALTH AND WEALTH CONSIDERED IN DECISION MAKING? RESULTS FROM A QUALITATIVE STUDY. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 449-456. | 0.2 | 4 |
| 78 | The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?. <i>SSRN Electronic Journal</i> , 2012, , . | 0.4 | 3 |
| 79 | Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria. <i>Oxford Review of Economic Policy</i> , 2016, 32, 64-87. | 1.0 | 3 |
| 80 | ASSESSING VALUE, BUDGET IMPACT, AND AFFORDABILITY IN ASIA. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 315-322. | 0.2 | 3 |
| 81 | RELATIVE EFFECTIVENESS IN BREAST CANCER TREATMENT: A HEALTH PRODUCTION APPROACH. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 371-379. | 0.2 | 2 |
| 82 | Policy perspectives on alternative models for pharmaceutical rebates: a report from the Institute for Clinical and Economic Review Policy Summit. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 1045-1054. | 0.6 | 2 |
| 83 | Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB. <i>BMJ Global Health</i> , 2020, 5, e002061. | 2.0 | 2 |
| 84 | Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al.. <i>Medical Decision Making</i> , 2021, 41, 255-257. | 1.2 | 2 |
| 85 | Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 2 |
| 86 | ???The Pros and Cons of a Single Euro-Price for Drugs??? and ???The Economics of Parallel Trade???. <i>Pharmacoeconomics</i> , 1998, 14, 135-137. | 1.7 | 1 |
| 87 | Measuring Value: Pharmacoeconomics Theory and Practice. , 2012, , . | | 1 |
| 88 | The use of pay-for-performance for drugs: Can it improve incentives for innovation?. , 2011, , 69-80. | | 1 |
| 89 | Joint Disease Management Ventures in the UK. <i>Journal of Integrated Care</i> , 1999, 3, 71-78. | 0.3 | 0 |
| 90 | Incentives for R&D for New Antimicrobial Drugs. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 91 | Health Economic Perspectives of Genomics. , 2016, , 83-117. | | 0 |
| 92 | El uso del pago por resultados para los fármacos: ¿Puede mejorar los incentivos para la innovación?. , 2012, , 79-91. | | 0 |
| 93 | Comparative and Relative Effectiveness: A Challenge for Health Systems, Regulators, or Pharmaceutical Companies?. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 94 | Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases. Applied Economics Letters, 0, , 1-5. | 1.0 | 0 |